C. difficile

Debra Goff, PharmD, FIDSA, FCCP, infectious diseases specialist at the Ohio State University Wexner Medical Center, discusses Clostridioides difficile awareness and potential future treatments.

Comprehensive discussion on the identification of Clostridioides difficile infection, the spectrum of disease, and overall epidemiology.

The panel reflects on how disruption of the gut microbiome leads to the proliferation of Clostridioides difficile.

Shared insight on how disruption of the gut microbiome may occur based on antibiotic exposure, environmental factors, and diet.

Opening their discussion on Clostridioides difficile, experts provide an overview on the gut microbiome and colonization resistance.

PRISM-EXT shows data consistent with those of PRISM3, which provided significant improvement compared with the placebo through 8 weeks and 24 weeks post-treatment.

SER-109, an investigational, oral, biologically-sourced microbiome therapeutic designed to reduce recurrence of C. difficile infection (CDI), demonstrated a 31.1% absolute reduction in the rate of CDI recurrence over 12 weeks compared to placebo

The concentration of C. diff toxins in the stool was linked to how sick patients were at the time of diagnosis and was associated with adverse outcomes, including the risk of infection returning after treatment.

A diagnosis of Clostridioides difficile infection does not instantly require treatment, but new guidelines include recommendations for treatment when warranted.

Lindy Bancke, PharmD, head of clinical development at Rebiotix Inc, said the clinical development program of RBX2660 is showing promise in the treatment of recurrent C. Difficile infection.

Investigators from the University of Houston find that 45% of the positive samples were from the soles of shoes.

Trials show a consistent efficacy profile and a consistent safety profile for RBX2660 in reducing the recurrence of C. difficile infection.

Although there are several conditions known to be risk factors for clostridium difficile, data on the link between malignancy and clostridium difficile are limited.

Individuals in a study who received the food with BB-12 probiotic retained beneficial metabolites produced by the microbiota.

Ten quiz questions to assess your knowledge on common symptoms and treatments for Clostridioides difficile.

From an economic perspective, C. difficile has a staggering financial impact on the US health care system, as well on the patients infected.

A study found individuals receiving probiotics had a decrease in C. difficile diagnosed in stool samples than those who did not receive probiotics.

The treatment was also well-tolerated, with a similar safety profile to placebo, according to the investigators.

Hospitalizations related to C. diff infections can cost more than twice as much as the average hospitalization and can extend patients’ stays by an average of 3.6 days.

Ridinilazole is not currently approved for use by any regulatory authority.

C difficile colonization rates among children were greatest at 6 to 12 months of age but decreased among children older than 5 years of age.

Bezlotoxumab is administered to prevent Clostridium difficile infection from recurring in patients who are receiving treatment for the infection and are at risk for recurrence.

Study findings could offer a new approach to the toxin-based approach of other C. difficile vaccines in development.

This action follows a recently completed phase 2a clinical trial, which demonstrated that 100% of the 10 enrolled patients met the study's primary and secondary efficacy endpoints of clinical cure at end of treatment as well as sustained clinical cure with no recurrence of CDI when examined on a 28-day follow-up visit.

Recurrent C. diff infections were observed in 16% of patients who received bezlotoxumab, compared with 29% of patients who received standard of care alone.

Investigators found that the therapeutic mechanism for bezlotoxumab, the only FDA-approved anti-TcdB antibody, is sensitive to escaping mutations in some bacterial strains.

Panelists also recommended the use of bezlotoxumab as a co-intervention with standard of care antibiotics in patients with a recurrent C. diff infection within the past 6 months.

Pharmacists should educate themselves about the options available to help patients manage this bacterium that causes severe diarrhea and colitis.

Researchers observed the structure of a lethal toxin produced by certain strains of Clostridium difficile bacteria.

Adult patients with Clostrioides difficile infection who received hematopoietic stem cell transplant also benefitted from frontline medications fidaxomicin or oral vancomycin.